[ Title ]
- Circulating tumor cells (Ctc) and kras mutant circulating free Dna
(cfdna) detection in peripheral blood as biomarkers in patients
diagnosed with exocrine pancreatic cancer
[ Author ]
- Earl, J
Garcia-Nieto, S
Martinez-Avila, JC
Montans, J
Sanjuanbenito, A
Rodriguez-Garrote, M
Lisa, E
Mendia, E
Lobo, E
Malats, N
Carrato, A
Guillen-Ponce, C
[ Abstract ]
- Background: Pancreatic cancer remains one of the most difficult cancers
to treat with the poorest prognosis. The key to improving survival rates
in this disease is early detection and monitoring of disseminated and
residual disease. However, this is hindered due to lack reliable
diagnostic and predictive markers which mean that the majority of
patients succumb to their condition within a few months.
Methods: We present a pilot study of the detection circulating free DNA
(cfDNA) combined with tumor specific mutation detection by digital PCR
as a novel minimally invasive biomarker in pancreatic ductal
adenocarcinoma (PDAC). This was compared to the detection of CTC by the
CellSearch (R) system and a novel CTC enrichment strategy based on CD45
positive cell depletion. The aim of the study was to assess tumor
specific DNA detection in plasma and CTC detection as prognostic markers
in PDAC.
Results: We detected KRAS mutant cfDNA in 26 % of patients of all stages
and this correlated strongly with Overall Survival (OS), 60 days (95 %
CI: 19-317) for KRAS mutation positive vs 772 days for KRAS mutation
negative (95 % CI: 416-1127). Although, the presence of CTC detected by
the CellSearch (R) system did correlate significantly with OS, 88 days
(95 % CI: 27-206) CTC positive vs 393 days CTC negative (95 % CI:
284-501), CTC were detected in only 20 % of patients, the majority of
which had metastatic disease, whereas KRAS mutant cfDNA was detected in
patients with both resectable and advanced disease.
Conclusions: Tumor specific cfDNA detection and CTC detection are
promising markers for the management of patients with PDAC, although
there is a need to validate these results in a larger patient cohort and
optimize the detection of CTC in PDAC by applying the appropriate
markers for their detection.
[ URL ]
- http://apps.webofknowledge.com/InboundService.do?SID=W1jSF44enaWOQu3pnYX&product=WOS&UT=WOS%3A000363377100022&SrcApp=Alerting&DestFail=http%3A%2F%2Fwww.webofknowledge.com&Init=Yes&action=retrieve&SrcAuth=Alerting&customersID=Alerting&Func=Frame&IsProductCode=Yes&mode=FullRecord